Bookmark

Add to MyYahoo RSS

Isis Pharmaceuticals News

News on Isis Pharmaceuticals (Ticker: ISIS) continually updated from thousands of sources around the net.

49 min ago | AmericanBankingNews.com

Isis Pharmaceuticals Inc 1,800 Shares of Regulus Therapeutics Stock

Regulus Therapeutics Director Isis Pharmaceuticals Inc 1,800 shares of the company's stock in a transaction that occurred on Wednesday, July 9th.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Wed Jul 02, 2014

BioSpace

Isis Pharmaceuticals, Inc. Earns $1 Million From GlaxoSmithKline For...

"Our collaboration with GSK has been very productive resulting in three novel antisense drugs in our pipeline.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, GlaxoSmithKline, Hepatitis, Health, Liver Cancer

Contract Pharma Breaking News

Isis Earns GSK Milestone

Isis Pharmaceuticals, Inc. has earned a $1 million payment from GlaxoSmithKline for the advancement of its development program for antisense drugs to treat hepatitis B virus .

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, GlaxoSmithKline, Hepatitis, Health

Thu Jun 26, 2014

Pharmaceutical Online

Isis Receives $1M Milestone From GSK For FAP Drug

Isis Pharmaceuticals announced this week that it has earned a $1 million milestone payment from GlaxoSmithKline after advancing its investigational drug ISIS-TTR Rx in a Phase II/III study in patients with familial amyloid polyneuropathy .

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, GlaxoSmithKline, Genetics

Wed Jun 25, 2014

AmericanBankingNews.com

Insider Selling: ISIS Pharmaceuticals SVP Sells 11,200 Shares of Stock

ISIS Pharmaceuticals SVP C Frank Bennett sold 11,200 shares of the company's stock in a transaction dated Monday, June 23rd.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Tue Jun 24, 2014

BioSpace

Isis Pharmaceuticals, Inc. Earns $1 Million From GlaxoSmithKline For Advancing ISIS-TTR Rx

ISIS-TTRRx is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, GlaxoSmithKline, Genetics, Marketing

Mon Jun 23, 2014

The Motley Fool

Better Buy: Isis Pharmaceuticals vs. Arrowhead Research

Earlier this year, clinical-stage biotechs fell in dramatic fashion, as investors turned toward bigger health-care names generating revenue from approved products.

Comment?

Related Topix: Biotech, Arrowhead Research, Medicine, Healthcare Industry, Healthcare Law, Law, Genetics

Thu Jun 19, 2014

Benzinga

ISIS Pharma Trades Up Premarket; NYT Says Has Potential Heart Attack Drug

Isis Pharmaceuticals gained more than four percent in pre-market trading after information related to its pipeline drug for lowering triglycerides landed on the New York Times' front page.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Publishing, Media, New Times

Wed Jun 18, 2014

Hispanic Business

Isis Pharmaceuticals Earns $15 Million from AstraZeneca for Initiation of Phase 1 Study of ISIS-AR Rx

ISIS-AR is an antisense drug designed to treat patients with prostate cancer by inhibiting the production of the androgen receptor .

Comment?

Related Topix: Medicine, Cancer, Health, Prostate Cancer, Biotech, Healthcare Industry

Mon Jun 16, 2014

Applied Clinical Trials

Isis Pharmaceuticals Reports Final Phase 2 Data on Isis-GCGR RX...

Up to 2.25 percentage point reduction in HbA1c achieved after only 13 weeks of dosing Treated patients achieved statistically significant reductions in measures of glucose control Isis to host an investor event and live webcast at 6:30 a.m. PDT on Monday, June 16 in San Francisco Isis Pharmaceuticals Reports Final Phase 2 Data on ISIS-GCGR RX ... (more)

Comment?

Related Topix: Biotech, Healthcare Industry, Diabetes, Health, Metformin (generic), Glucophage

Fri Jun 13, 2014

Seeking Alpha

A Pax Romana May Be Bad For Markets

Increasing geopolitical conflict disrupts the vacuum that puts the current market at risk for unexpected moves in the absence of obvious catalysts.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Hispanic Business

Isis Pharmaceuticals Inc Files (8-K) Disclosing Submission of Matters to a Vote of Security Holders

Proposal 2: Ratification of the appointment of a director to hold office until the 2015 Annual Meeting: BROKER FOR WITHHELD ABSTAIN NON-VOTES Breaux Castleman 82,210,674 2,070,994 139,740 17,393,063 appointment by affirmative votes by a majority of the votes of the shares represented in person or by proxy at the meeting and entitled to vote in the ... (more)

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Thu Jun 12, 2014

AmericanBankingNews.com

ISIS Pharmaceuticals CEO Unloads $368,060 in Stock

ISIS Pharmaceuticals CEO Stanley T. Crooke sold 11,000 shares of the company's stock in a transaction dated Tuesday, June 10th.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

•••
•••
•••
•••
•••

Ashburn Jobs

•••
•••
•••
•••